Cancer specific survival in patients with sickle cell disease.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
04 2019
Historique:
received: 15 08 2018
accepted: 12 10 2018
pubmed: 24 11 2018
medline: 26 2 2020
entrez: 24 11 2018
Statut: ppublish

Résumé

Sickle cell disease (SCD) patients have a higher incidence of certain cancers, but no studies have determined the impact of cancer on survival among SCD patients. SCD patients (n = 6423), identified from state-wide hospitalisation data, were linked to the California Cancer Registry (1988-2014). Multivariable Cox proportional hazards regression was used to examine survival. Among SCD patients, a cancer diagnosis was associated with a 3-fold increased hazard of death. Compared to matched cancer patients without SCD, SCD was associated with worse overall survival, but not cancer-specific survival, suggesting that SCD cancer patients should be treated with similar therapeutic intent.

Identifiants

pubmed: 30467842
doi: 10.1111/bjh.15687
pmc: PMC8966490
mid: NIHMS1787249
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-132

Subventions

Organisme : NHLBI NIH HHS
ID : R21 HL129033
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000035C
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U58 DP003862
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000034C
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201000140C
Pays : United States

Informations de copyright

© 2018 British Society for Haematology and John Wiley & Sons Ltd.

Références

J R Soc Med. 2016 Aug;109(8):303-9
pubmed: 27325377
Blood Adv. 2017 Jul 11;1(16):1287-1295
pubmed: 29296770
N Engl J Med. 1991 Jul 4;325(1):11-6
pubmed: 1710777
Medicine (Baltimore). 2005 Nov;84(6):363-376
pubmed: 16267411
Blood. 2017 Sep 28;130(13):1597-1599
pubmed: 28830890
Cancer Causes Control. 2001 Oct;12(8):703-11
pubmed: 11562110
Br J Haematol. 2017 Jul;178(2):319-326
pubmed: 28369826

Auteurs

Ann Brunson (A)

Center for Oncology and Hematology Outcomes Research and Training (COHORT), Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA, USA.

Theresa H M Keegan (THM)

Center for Oncology and Hematology Outcomes Research and Training (COHORT), Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA, USA.

Anjlee Mahajan (A)

Center for Oncology and Hematology Outcomes Research and Training (COHORT), Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA, USA.

Susan Paulukonis (S)

CA Rare Disease Surveillance Program, Public Health Institute, Richmond, CA, USA.

Ted Wun (T)

Center for Oncology and Hematology Outcomes Research and Training (COHORT), Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA, USA.
UC Davis Clinical and Translational Science Center, Sacramento, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH